Key result
Sacubitril/valsartan was associated with longer life expectancy and a higher incremental cost-effectiveness ratio compared to ACE inhibitors in patients with HFrEF.
Why the study?
The study was conducted to compare the cost-effectiveness of sacubitril/valsartan with ACE inhibitors for treating chronic HFrEF from published articles and explore the methodology applied in the studies.
Is sacubitril/valsartan cost-effective compared to ACE inhibitors in patients with HFrEF?
Systematic Review (n=15)
Yes
Is sacubitril/valsartan cost-effective compared to ACE inhibitors in patients with HFrEF?
A systematic review of cost-effectiveness analyses demonstrates that sacubitril/valsartan provides longer life expectancy and is cost-effective compared to ACE inhibitors in patients with HFrEF.
Answers are grounded in this paper and cite their sources.
Sacubitril/valsartan yields higher ICERs with survival gains in reviewed CEAs; leaves open standardized methods and generalizability across settings.
Objectives: The goal of this study was to compare cost-effectiveness of sacubitril/valsartan with angiotensin-converting enzyme (ACE) inhibitors for treating chronic heart failure patients with reduced ejection fraction (HFrEF) from the published articles and explore the methodology applied in the studies. Methods: Systematic research was conducted in February 2021 using PubMed, Cochrane, and EBSCO. A combination of MeSH terms of “cost-effectiveness analysis,” “heart failure with reduced ejection fraction,” “sacubitril valsartan,” and “angiotensin converting enzyme inhibitor” was employed. The review selected for articles published in the last five years in English. Results: A total of 15 studies were included in this review. We found that these studies had been conducted in 12 different countries. The United States had the greatest number of publications (5), followed by the Netherlands (2). The study method most used was the Markov decision model (73%). Almost all studies produced ICERs and QALYs that were numerically high. Conclusions: The use of sacubitril/valsartan associates with longer life expectancy and incremental cost-effectiveness ratio than angiotensin-converting enzyme inhibitors.
No takes yet. Share an insight, caveat, or question.
Febrinasari et al. (2022) conducted a systematic review in Heart failure with reduced ejection fraction (HFrEF) (n=15). Sacubitril/valsartan vs. Angiotensin-converting enzyme (ACE) inhibitors was evaluated on Cost-effectiveness (ICERs and QALYs). Sacubitril/valsartan was associated with longer life expectancy and a higher incremental cost-effectiveness ratio compared to ACE inhibitors in patients with HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: